Search Login Register

rituximab (Mabthera) Summary

Description: a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma; has immunosuppressive activity

Also Known As: Mabthera; Rituxan; CD20 antibody, rituximab; Genentech brand of rituximab; Hoffmann-La Roche brand of rituximab Show All >>

Networked: 5362 relevant articles (1155 outcomes, 932 trials/studies) for this Drug

Key Diseases for which rituximab is Relevant

  1. Lymphoma (Lymphomas) : 150 outcomes 139 studies in 876 results
  2. Non-Hodgkin Lymphoma (Lymphosarcoma) : 128 outcomes 146 studies in 764 results
  3. B-Cell Lymphoma (Lymphoma, B Cell) : 102 outcomes 59 studies in 444 results
  4. Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell) : 90 outcomes 96 studies in 460 results
  5. Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) : 72 outcomes 84 studies in 365 results
Show All >>

Drugs Related to rituximab

  1. Cyclophosphamide (Cytoxan)
  2. Vincristine (Oncovin)
  3. Doxorubicin (Adriamycin)
  4. Prednisone (Sone)
  5. fludarabine
  6. rituximab (Mabthera)
  7. bendamustine
  8. CD20 Antigens
  9. Methotrexate (Mexate)
  10. Prednisolone (Predate)
Show All >>

Therapies Related to rituximab

  1. Drug Therapy (Chemotherapy)
  2. Aftercare (After-Treatment)
  3. Stem Cell Transplantation
  4. Transplants (Transplant)
  5. Immunotherapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2013 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.